Issue 21 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

32

No.

21

June 02, 2006Jun 02, 2006

Free

DOWNLOAD THE PDF

FDA Didn’t Tell Advisors About Data Linking Obesity Drug With Precancerous Lesions.

Scientists, Public Citizen Urge FDA To Ban Sale Of Obesity Drug Orlistat.

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

John Niederhuber Named Acting NCI Director.

Recent Issues

Volume 52 | Issue 30 - July 31, 2026

Volume 52 | Issue 29 - July 24, 2026

Volume 52 | Issue 28 - July 17, 2026

Volume 52 | Issue 27 - July 10, 2026

Volume 52 | Issue 26 - July 02, 2026

Volume 52 | Issue 25 - June 26, 2026